RESUMO
OBJECTIVE: This study aimed to investigate and compare the pregnancy and live birth rates in IVF cycles of frozen-thawed embryo transfers and fresh embryo transfers in a group of women with a high risk of Ovarian hyperstimulation syndrome (OHSS). MATERIAL AND METHODS: The study group consisted of 254 women with a high level of response to controlled ovarian hyperstimulation. The patients who received fresh cycle embryo transfers with calcium infusions are referred to as the Fresh Ca+ group, and those without the calcium therapy are called the Fresh Ca- group; and we used correspondingly similar terminology for the Frozen group. RESULTS: We observed no statistically significant differences between the cycles of fresh and frozen-thawed embryo transfers in patients with a high risk of OHSS in terms of implantation, clinical pregnancy, and live birth rates. Furthermore, these implantation, clinical pregnancy and live birth rates were not different in the cycles with or without calcium treatment. There was no statistical difference in the OHSS rates between the fresh and frozen-thawed cycles; although, the OHSS rates were less in the two calcium infusion groups (Fresh Ca+ and Frozen-thawed Ca+) than in the without-calcium group. There was no OHSS development in the subjects of the Frozen-thawed Ca+ group. CONCLUSION: Our study results suggest that fresh and frozen-thawed embryo transfers have similar IVF results in patients with a high risk of OHSS. Calcium infusion is beneficial in preventing OHSS without altering pregnancy rates. Both IVF protocols with calcium infusion can safely be applied in high-responder patients without lowering success rates.
Assuntos
Blastocisto , Gluconato de Cálcio/administração & dosagem , Criopreservação , Transferência Embrionária , Fármacos para a Fertilidade Feminina/administração & dosagem , Fertilidade/efeitos dos fármacos , Infertilidade/terapia , Indução da Ovulação , Injeções de Esperma Intracitoplásmicas , Adulto , Gluconato de Cálcio/efeitos adversos , Técnicas de Cultura Embrionária , Transferência Embrionária/efeitos adversos , Feminino , Fármacos para a Fertilidade Feminina/efeitos adversos , Humanos , Infertilidade/diagnóstico , Infertilidade/fisiopatologia , Infusões Intravenosas , Nascido Vivo , Síndrome de Hiperestimulação Ovariana/etiologia , Síndrome de Hiperestimulação Ovariana/fisiopatologia , Síndrome de Hiperestimulação Ovariana/prevenção & controle , Indução da Ovulação/efeitos adversos , Gravidez , Taxa de Gravidez , Estudos Retrospectivos , Fatores de Risco , Injeções de Esperma Intracitoplásmicas/efeitos adversos , Resultado do Tratamento , Adulto JovemRESUMO
INTRODUCTION: Calcium gluconate extravasation is a process, which, while not common, occurs more frequently in neonatal intensive care units. The aim of this study is to present a number of cases of calcium gluconate extravasation, which have occurred in our hospital, and to carry out a review of those clinical cases published in the literature to obtain relevant epidemiological data. METHODS: Data were gathered on the medical histories of 5 patients who presented lesions secondary to calcium gluconate extravasation in our center. A review of the literature was also performed to include clinical cases of calcium gluconate extravasation already published. RESULTS: Data were collected on 60 cases published in 37 articles. Most patients (55%) were neonates. The average age of these neonates was 8 days. The commonest location of injuries was the back of the hand and wrist (42%). The 2 most frequent symptoms were the appearance of erythema (65%) and swelling/edema (48%) followed by the appearance of skin necrosis (47%), indurated skin (33%), and yellow-white plaques or papules (33%). Most cases are cured within a period of 3 to 6 months. Fifty percent of patients required surgery, and in 13% of cases, skin grafts were performed. The most frequent histological finding was the presence of calcium deposits. Other histological findings described were the presence of necrosis, lymphohistiocytic infíltrate, and granulomas. Most histological findings were located in the dermis. Most x-rays showing calcium deposits had been performed at 3 to 4 weeks. CONCLUSIONS: Calcium gluconate extravasation is a process, which, although infrequent, is associated with serious skin and soft-tissue lesions, mainly affecting infants. Further studies are needed to determine possible specific procedures to be carried out in these cases.
Assuntos
Gluconato de Cálcio/efeitos adversos , Extravasamento de Materiais Terapêuticos e Diagnósticos/etiologia , Hipocalcemia/tratamento farmacológico , Pele/efeitos dos fármacos , Idoso , Gluconato de Cálcio/administração & dosagem , Extravasamento de Materiais Terapêuticos e Diagnósticos/fisiopatologia , Feminino , Seguimentos , Humanos , Hipocalcemia/diagnóstico , Incidência , Lactente , Recém-Nascido , Infusões Intravenosas , Masculino , Medição de Risco , Estudos de Amostragem , Pele/patologiaRESUMO
BACKGROUND: A novel therapeutic management of osteoarthritis (OA) of the knee was assessed. The study aimed to evaluate the effect of monthly sodium bicarbonate with a single (SBCG1) or double dose (SBCG2) of calcium gluconate injections on OA of the knee; as well as the efficacy and safety of both SBCG interventions in the long term. METHODS: A double-blind parallel-group clinical trial with 74 knee OA patients was performed during 12 months, both SBCG interventions were followed-up for another 6mo after intervention. The outcome variables were the Western Ontario-McMaster University Osteoarthritis Index (WOMAC), the Lequesne's functional index and joint-space width changes from serial radiographs. RESULTS: After 12 months, group SBCG1 decreased -14.8 (95% CI:-14.2, -17.0) and group SBCG2 decreased -14.6 (-16.9, -12.4) in the global WOMAC score, the mean changes represent 80% and 82% lessened pain, respectively. In the Lequesne Functional Index scale, SBCG1 decreased -11.9 (-10.4, -14.2) and SBCG2 decreased -11.9 (-13.8, -10.0), representing 66 and 69% of improvement. Both mean scores were maintained after intervention discontinued. SBCG2 improved the knees' joint space width more than SBCG1 at 3 and 18 months. Both SBCG interventions were well tolerated after 12 months of treatment CONCLUSION: A solution of sodium bicarbonate and calcium gluconate is effective on reducing the symptoms associated with OA. Its beneficial effect is maintained for one year of continuous monthly administration and at least for 6 months after the administration is discontinued. When the dose of calcium gluconate is increased, it prevents further narrowing of joint-space. TRIAL REGISTRATION: Clinicaltrials.gov NCT00977444 September 11, 2009.
Assuntos
Gluconato de Cálcio/administração & dosagem , Osteoartrite do Joelho/tratamento farmacológico , Bicarbonato de Sódio/administração & dosagem , Adulto , Gluconato de Cálcio/efeitos adversos , Progressão da Doença , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Injeções Intra-Articulares , Masculino , Pessoa de Meia-Idade , Osteoartrite do Joelho/fisiopatologia , Dor/tratamento farmacológico , Dor/etiologia , Bicarbonato de Sódio/efeitos adversosAssuntos
Calcinose/etiologia , Gluconato de Cálcio/efeitos adversos , Recém-Nascido Prematuro , Síndrome do Desconforto Respiratório do Recém-Nascido/tratamento farmacológico , Dermatopatias/etiologia , Calcinose/diagnóstico , Gluconato de Cálcio/administração & dosagem , Seguimentos , Humanos , Doença Iatrogênica , Recém-Nascido , Infusões Intravenosas/efeitos adversos , Unidades de Terapia Intensiva Neonatal , Masculino , Síndrome do Desconforto Respiratório do Recém-Nascido/diagnóstico , Medição de Risco , Pele/patologia , Dermatopatias/diagnósticoRESUMO
The combination use of dexamethasone and calcium gluconate can be applied to hypersensitivity. Severe hypokalemia is a usual complication of dexamethasone and calcium gluconate therapy, which occurs frequently with therapeutic use. Fatal cases, accidental and intentional, occur frequently in forensic practice. The current case report presented a 43-year-old man with diabetes mellitus with infection, to whom dexamethasone and calcium gluconate were administered in the private clinic. With the development of such clinical symptoms of severe hypokalemia as quadriplegia, he was confirmed to have severe hypokalemia through a biochemical test before dying of arrhythmia. And also it presented pathophysiologic mechanism underlying severe hypokalemia as well as suggestions for clinical practice regarding combination use of dexamethasone and calcium gluconate.
Assuntos
Anti-Inflamatórios/efeitos adversos , Gluconato de Cálcio/efeitos adversos , Dexametasona/efeitos adversos , Hipopotassemia/induzido quimicamente , Adulto , Diabetes Mellitus , Evolução Fatal , Humanos , MasculinoRESUMO
Calcinosis cutis is a rare disorder resulting from the precipitation and deposition of insoluble calcium and phosphate salts (hydroxyapatite crystals) in the dermis and subcutaneous tissue. It is generally divided into four main groups on the basis of etiology and pathogenesis. Clinical presentation of cutaneous calcinosis cutis varies according to the diagnosis and the underlying process. We report a case of calcinosis cutis of the heel in which both the extravasation of a calcium gluconate infusion and renal failure could have promoted the development of calcinosis cutis.
Assuntos
Calcinose/etiologia , Gluconato de Cálcio/efeitos adversos , Eritema/etiologia , Extravasamento de Materiais Terapêuticos e Diagnósticos/complicações , Dermatoses do Pé/etiologia , Úlcera do Pé/etiologia , Calcinose/diagnóstico por imagem , Gluconato de Cálcio/administração & dosagem , Gluconato de Cálcio/uso terapêutico , Cateterismo Periférico , Derme/diagnóstico por imagem , Feminino , Úlcera do Pé/diagnóstico por imagem , Humanos , Hiperfosfatemia/tratamento farmacológico , Hiperfosfatemia/etiologia , Hipopotassemia/tratamento farmacológico , Hipopotassemia/etiologia , Lactente , Infusões Intravenosas , Falência Renal Crônica/etiologia , Falência Renal Crônica/metabolismo , Falência Renal Crônica/terapia , Nefrectomia , Diálise Peritoneal , Rim Policístico Autossômico Recessivo/complicações , Rim Policístico Autossômico Recessivo/cirurgia , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/etiologia , RadiografiaRESUMO
Sodium thiosulfate has been successfully used to treat calcyphilaxis in adults and children, but its effect on iatrogenic calcinosis cutis secondary to extravasation of calcium solutions is less known. We describe a 5-year-old boy with acute lymphoblastic leukemia who developed severe calcinosis cutis in the right forearm and hand, and in the left leg and foot after extravasation of calcium gluconate during treatment for tumor-lysis-syndrome-related hypocalcaemia. Surgical debridement, local wound care, hyperbaric oxygen therapy, and sodium thiosulfate infusion achieved a complete healing of all lesions in an eight-month period with a short discontinuation of chemotherapy. No functional or sensitive impairment remained.
Assuntos
Calcinose/tratamento farmacológico , Quelantes/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células T Precursoras/terapia , Dermatopatias/tratamento farmacológico , Tiossulfatos/administração & dosagem , Calcinose/etiologia , Gluconato de Cálcio/efeitos adversos , Pré-Escolar , Extravasamento de Materiais Terapêuticos e Diagnósticos/complicações , Humanos , Infusões Intravenosas , Masculino , Dermatopatias/etiologiaRESUMO
The extravasation of a calcium solution into soft tissue constitutes a medical emergency, and a lack of adequate management can lead to significant functional and cosmetic sequelae. Here, we report on the management of and long-term outcome in two children who experienced calcium infusion leakage. We also describe the emergency procedures used in cases of extravasation and discuss the role of negative pressure wound therapy as an appropriate adjunct to conventional techniques for dealing with serious extravasation-related injuries.
Assuntos
Cloreto de Cálcio/efeitos adversos , Gluconato de Cálcio/efeitos adversos , Extravasamento de Materiais Terapêuticos e Diagnósticos/complicações , Tratamento de Ferimentos com Pressão Negativa , Lesões dos Tecidos Moles/etiologia , Lesões dos Tecidos Moles/terapia , Adolescente , Cloreto de Cálcio/administração & dosagem , Gluconato de Cálcio/administração & dosagem , Extravasamento de Materiais Terapêuticos e Diagnósticos/diagnóstico , Humanos , Recém-Nascido , Infusões Intravenosas , MasculinoRESUMO
BACKGROUND: Calcium gluconate extravasation is a process that can cause serious lesions, such as necrosis and calcification of the soft tissues. The aim of the present study was to analyze the beneficial effects of four possible local antidotes for calcium gluconate extravasation: hyaluronidase, sodium thiosulfate, triamcinolone acetonide, and physiologic saline solution. METHODS: Seventy-four BALB/c mice were used in the study. The substances selected for use in this study were calcium gluconate (4.6 mEq/ml), hyaluronidase (1500 IU/ml), sodium thiosulfate (25%), triamcinolone acetonide (40 mg/ml 0.5 mg/kg), and saline solution 0.9%. Five minutes were allowed to lapse after the calcium gluconate infiltration, and then an antidote was infiltrated. After 3 weeks, a skin biopsy was performed and a radiographic and histologic study was carried out. RESULTS: Only in the group infiltrated with sodium thiosulfate did all skin lesions disappear after the 3-week period after infiltration. In the radiographic study, calcium deposits larger than 0.5 mm were observed in 40 percent of cases without an antidote, in 33 percent with triamcinolone acetonide, in 13 percent with a saline solution, and in none with thiosulfate and hyaluronidase. In the histologic study, calcium deposits were found in 53 percent of cases without antidote, 100 percent of cases with triamcinolone acetonide, 33 percent of cases with saline solution, and 13 percent of cases with sodium thiosulfate or hyaluronidase. CONCLUSION: Sodium thiosulfate and hyaluronidase prevent the development of calcium deposits after calcium gluconate extravasation.
Assuntos
Antídotos/uso terapêutico , Calcinose/induzido quimicamente , Calcinose/prevenção & controle , Gluconato de Cálcio/efeitos adversos , Dermatopatias/induzido quimicamente , Dermatopatias/prevenção & controle , Animais , Hialuronoglucosaminidase/uso terapêutico , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Estudos Prospectivos , Solução Salina/uso terapêutico , Tiossulfatos/uso terapêutico , Resultado do Tratamento , Triancinolona Acetonida/uso terapêuticoRESUMO
Using calcium salts in management of amlodipine overdose is challenging. A 25-year-old male with known history of adult polycystic kidney disease presented with hypotension, tachycardia, and intact neurological status after ingestion of 450 mg of amlodipine. Immediately, normal saline infusion and norepinephrine were initiated. Two grams of calcium gluconate was injected, followed by intravenous infusion of 1.16 mg/kg/h. The patient was put on insulin-glucose protocol to maintain euglycemia and hyperinsulinemia. Electrocardiography demonstrated junctional rhythm. Serum creatinine was 2.5 mg/dL with metabolic acidosis. By the end of 24 h post-admission, his consciousness, blood pressure, and urine output were normal. Almost 32 h post-admission, he became disoriented and his oxygen saturation decreased and therefore was mechanically ventilated. Second chest X-ray showed pulmonary edema. Serum calcium level increased to 26.1 mg/dL. Calcium was discontinued, and furosemide infusion and calcitonin were intravenously administrated. Urine output increased and hemodialysis improved pulmonary edema and serum calcium level with no change in consciousness. Three days after admission, the patient became anuric and developed multi-organ failure and died 5 days post-admission. To avoid the consequences of excessive infusion of calcium in renal failure patients, the minimum calcium dose with close monitoring is recommended.
Assuntos
Anlodipino/intoxicação , Bloqueadores dos Canais de Cálcio/intoxicação , Gluconato de Cálcio/efeitos adversos , Hipercalcemia/induzido quimicamente , Hipotensão/tratamento farmacológico , Doença Iatrogênica , Taquicardia/tratamento farmacológico , Adulto , Anlodipino/administração & dosagem , Bloqueadores dos Canais de Cálcio/administração & dosagem , Gluconato de Cálcio/administração & dosagem , Eletrocardiografia , Evolução Fatal , Humanos , Hipercalcemia/sangue , Hipercalcemia/diagnóstico , Hipercalcemia/fisiopatologia , Hipotensão/induzido quimicamente , Hipotensão/diagnóstico , Hipotensão/fisiopatologia , Rim/fisiopatologia , Falência Renal Crônica/complicações , Falência Renal Crônica/fisiopatologia , Masculino , Insuficiência de Múltiplos Órgãos/induzido quimicamente , Fatores de Risco , Suicídio , Taquicardia/induzido quimicamente , Taquicardia/diagnóstico , Taquicardia/fisiopatologiaRESUMO
OBJECTIVE: The diagnosis of primary hyperparathyroidism (PHP) can be difficult in patients with normal plasma calcium or parathyroid hormone (PTH) levels. We perfected a standardized short-time i.v. calcium loading test in healthy controls (HC) and compared the results with those of patients with PHP. METHODS: Sixteen HC received 0.33 mmol/kg calcium gluconate intravenously for 3 h. Plasma calcium and serum PTH levels (assayed with immunoluminescent sandwich methods) were measured before, at the end of the infusion and 3 h later. Results were compared with those of 16 PHP patients. RESULTS: In HC, basal total plasma calcium (mean +/- s.e.m.) was 2.33 +/- 0.02 mmol/l. At the end of calcium loading, calcemia reached 3.21 +/- 0.05 mmol/l and decreased to 2.94 +/- 0.08 mmol/l 3 h later. In PHP patients, basal plasma calcium was 2.54 +/- 0.03 mmol/l and reached similar values as in HC during the testing. Basal serum PTH levels were 32.5 +/- 3.3 ng/l in HC and 86.9 +/- 6.3 ng/l in PHP. At the end of calcium loading, they dropped to 8.8 +/- 0.6 ng/l (HC) and to 31.4 +/- 4.2 ng/l (PHP). Three hours later, they were 11.6 +/- 0.8 and 39.8 +/- 4.0 ng/l respectively. There was a cut-off in serum PTH values between the two groups at the end of calcium loading and 3 h later. CONCLUSION: The standardized short-time PTH suppression test appears reliable to differentiate healthy subjects from PHP whose serum PTH levels remain >14 and >23 ng/ml respectively at the end of loading and 3 h later. This well-tolerated and easily performed test could be used for the diagnosis of PHP in patients suspected for the disease despite the normality of some basal biological markers.
Assuntos
Gluconato de Cálcio , Cálcio/sangue , Hiperparatireoidismo Primário/sangue , Hiperparatireoidismo Primário/diagnóstico , Adulto , Idoso , Gluconato de Cálcio/administração & dosagem , Gluconato de Cálcio/efeitos adversos , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fósforo/sangue , Reprodutibilidade dos Testes , Albumina SéricaAssuntos
Calcinose/induzido quimicamente , Gluconato de Cálcio/efeitos adversos , Toxidermias/etiologia , Glândulas Écrinas , Doenças das Glândulas Sudoríparas/induzido quimicamente , Gluconato de Cálcio/administração & dosagem , Humanos , Hipocalcemia/tratamento farmacológico , Infusões Intravenosas , Masculino , Calcificação Vascular/induzido quimicamente , Adulto JovemAssuntos
Gluconato de Cálcio/uso terapêutico , Ornitina/uso terapêutico , Fenilalanina/uso terapêutico , Fosfatos/uso terapêutico , Desempenho Atlético , Gluconato de Cálcio/efeitos adversos , Suplementos Nutricionais , Fadiga/tratamento farmacológico , Humanos , Glicinas N-Substituídas/efeitos adversos , Glicinas N-Substituídas/uso terapêutico , Ornitina/farmacologia , Fenilalanina/metabolismo , Fenilalanina/farmacologia , Propilaminas/efeitos adversos , Propilaminas/uso terapêuticoRESUMO
In order to compare the effects of several experimental renal calcium oxalate stones formation models in rats and to find a simple and convenient model with significant effect of calcium oxalate crystals deposition in the kidney, several rat models of renal calcium oxalate stones formation were induced by some crystal-inducing drugs (CID) including ethylene glycol (EG), ammonium chloride (AC), vitamin D(3)[1alpha(OH)VitD(3), alfacalcidol], calcium gluconate, ammonium oxalate, gentamicin sulfate, L-hydroxyproline. The rats were fed with drugs given singly or unitedly. At the end of experiment, 24-h urines were collected and the serum creatinine (Cr), blood urea nitrogen (BUN), the extents of calcium oxalate crystal deposition in the renal tissue, urinary calcium and oxalate excretion were measured. The serum Cr levels in the stone-forming groups were significantly higher than those in the control group except for the group EG+L-hydroxyproline, group calcium gluconate and group oxalate. Blood BUN concentration was significantly higher in rats fed with CID than that in control group except for group EG+L-hydroxyproline and group ammonium oxalate plus calcium gluconate. In the group of rats administered with EG plus Vitamin D(3), the deposition of calcium oxalate crystal in the renal tissue and urinary calcium excretion were significantly greater than other model groups. The effect of the model induced by EG plus AC was similar to that in the group induced by EG plus Vitamin D(3). EG plus Vitamin D(3) or EG plus AC could stably and significantly induced the rat model of renal calcium oxalate stones formation.
Assuntos
Oxalato de Cálcio/urina , Cálculos Renais/metabolismo , Rim/metabolismo , Cloreto de Amônio/efeitos adversos , Cloreto de Amônio/metabolismo , Cloreto de Amônio/urina , Animais , Nitrogênio da Ureia Sanguínea , Cálcio/sangue , Cálcio/metabolismo , Cálcio/urina , Gluconato de Cálcio/efeitos adversos , Gluconato de Cálcio/metabolismo , Gluconato de Cálcio/urina , Oxalato de Cálcio/metabolismo , Creatinina/sangue , Cristalização , Modelos Animais de Doenças , Etilenoglicol/efeitos adversos , Etilenoglicol/metabolismo , Etilenoglicol/urina , Gentamicinas/efeitos adversos , Gentamicinas/metabolismo , Gentamicinas/urina , Hidroxicolecalciferóis/efeitos adversos , Hidroxicolecalciferóis/metabolismo , Hidroxicolecalciferóis/urina , Hidroxiprolina/efeitos adversos , Hidroxiprolina/metabolismo , Hidroxiprolina/urina , Rim/patologia , Cálculos Renais/induzido quimicamente , Cálculos Renais/prevenção & controle , Magnésio/metabolismo , Magnésio/urina , Masculino , Microscopia de Polarização , Oxalatos/efeitos adversos , Oxalatos/metabolismo , Oxalatos/urina , Fósforo/sangue , Distribuição Aleatória , Ratos , Ratos WistarRESUMO
This case report describes a rare differential diagnosis of soft-tissue infection in a neonate. Fever, pain, inflammation, and acute tenderness in the limb of a neonate signify acute infection or osteomyelitis unless proved otherwise. Iatrogenic calcinosis cutis presents with similar symptoms and signs; its diagnosis may be easily confused with an infective condition by an unwary orthopaedic surgeon. This report aimed to raise doctors' awareness on the presentation, aetiopathogenesis, and course of the relatively rare iatrogenic calcinosis cutis.
Assuntos
Calcinose/diagnóstico , Gluconato de Cálcio/efeitos adversos , Doença Iatrogênica , Dermatopatias/diagnóstico , Infecções dos Tecidos Moles/diagnóstico , Calcinose/induzido quimicamente , Gluconato de Cálcio/uso terapêutico , Diagnóstico Diferencial , Feminino , Humanos , Recém-Nascido , Infusões Intravenosas , Extremidade Inferior , Medição de Risco , Veia Safena , Convulsões/diagnóstico , Convulsões/tratamento farmacológico , Dermatopatias/induzido quimicamenteRESUMO
Calciphylaxis is a complication of chronic kidney disease characterized by necrotic lesion in the skin. Histological examination reveals microcalcification of medium-sized blood vessels. We report on a 21-month-old girl with end-stage renal disease with severe calcium-phosphate imbalance. Calciphylaxis process started when she received calcium gluconate intravenously the day before the surgery to correct hypocalcemia and continued progressively despite peritoneal dialysis and forced stopping calcium-containing medication. Pamidronate, 0.5 mg/kg/d, was administered for 6 days and then once a week for 5 weeks. After 1 week, the skin lesion started to heal and circulation improved, and after 6 weeks, all skin lesions completely recovered. Pamidronate was effective to stop calciphylaxis in this case with advanced renal insufficiency and severe calcium-phosphate imbalance. Medical or surgical debridement are not suggested and lesions might recover without scar by pamidronate.
Assuntos
Calciofilaxia/tratamento farmacológico , Gluconato de Cálcio/efeitos adversos , Difosfonatos/uso terapêutico , Hipocalcemia/tratamento farmacológico , Falência Renal Crônica/complicações , Biópsia , Calciofilaxia/diagnóstico , Calciofilaxia/etiologia , Desbridamento , Feminino , Humanos , Hipocalcemia/diagnóstico , Hipocalcemia/etiologia , Falência Renal Crônica/diagnóstico , Falência Renal Crônica/terapia , Pamidronato , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Cicatrização/efeitos dos fármacos , Adulto JovemRESUMO
The nano-composites of whey protein hydrolysate (WPH) chelated with calcium were fabricated in aqueous solution at 30 °C for 20 min, with the ratio of hydrolysate to calcium 15 : 1 (w/w). UV scanning spectroscopy, fluorescent spectroscopy, Fourier transform infrared spectroscopy, dynamic light scattering and atomic force microscopy were applied to characterize the structure of the WPH-calcium chelate. The nano-composites showed the successful incorporation of calcium into the WPH, indicating the interaction between calcium and WPH. The chelation of calcium ions to WPH caused molecular folding and aggregation which led to the formation of a WPH-calcium chelate of nanoparticle size, and the principal sites of calcium-binding corresponded to the carboxyl groups and carbonyl groups of WPH. The WPH-calcium chelate demonstrated excellent stability and absorbability under both acidic and basic conditions, which was beneficial for calcium absorption in the gastrointestinal tract of the human body. Moreover, the calcium absorption of the WPH-calcium chelate on Caco-2 cells was significantly higher than those of calcium gluconate and CaCl2 in vitro, suggesting the possible increase in calcium bioavailability. The findings suggest that the WPH-calcium chelate has the potential in making dietary supplements for improving bone health of the human body.
Assuntos
Conservadores da Densidade Óssea/química , Cálcio da Dieta/análise , Suplementos Nutricionais/análise , Absorção Intestinal , Nanocompostos/química , Hidrolisados de Proteína/química , Proteínas do Soro do Leite/química , Absorção Fisiológica , Sítios de Ligação , Conservadores da Densidade Óssea/administração & dosagem , Conservadores da Densidade Óssea/efeitos adversos , Conservadores da Densidade Óssea/metabolismo , Células CACO-2 , Quelantes de Cálcio/efeitos adversos , Quelantes de Cálcio/química , Cloreto de Cálcio/efeitos adversos , Cloreto de Cálcio/metabolismo , Gluconato de Cálcio/efeitos adversos , Gluconato de Cálcio/metabolismo , Cálcio da Dieta/administração & dosagem , Cálcio da Dieta/efeitos adversos , Cálcio da Dieta/metabolismo , Sobrevivência Celular , Fenômenos Químicos , Suplementos Nutricionais/efeitos adversos , Endopeptidases/metabolismo , Enterócitos/metabolismo , Humanos , Nanocompostos/efeitos adversos , Tamanho da Partícula , Dobramento de Proteína , Hidrolisados de Proteína/efeitos adversos , Hidrolisados de Proteína/metabolismo , Proteólise , Solubilidade , Proteínas do Soro do Leite/efeitos adversos , Proteínas do Soro do Leite/metabolismoRESUMO
Building on the work of the late John Myers, MD, the author has used an intravenous vitamin-and-mineral formula for the treatment of a wide range of clinical conditions. The modified "Myers' cocktail," which consists of magnesium, calcium, B vitamins, and vitamin C, has been found to be effective against acute asthma attacks, migraines, fatigue (including chronic fatigue syndrome), fibromyalgia, acute muscle spasm, upper respiratory tract infections, chronic sinusitis, seasonal allergic rhinitis, cardiovascular disease, and other disorders. This paper presents a rationale for the therapeutic use of intravenous nutrients, reviews the relevant published clinical research, describes the author's clinical experiences, and discusses potential side effects and precautions.